Ikena Oncology Inc. announced a 1-for-12 reverse stock split of its common stock, set to take effect on July 28, 2025. The company will rebrand as "ImageneBio, Inc." with the ticker symbol "IMA." This move will reduce outstanding shares from approximately 48.2 million to around 4 million, while maintaining the authorized share count and par value per share. Fractional shares will be settled with cash payments based on the closing price on July 24, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.